Japan Pharmaceutical Industry is Worth More Than USD 89 Billion, Reports GBI Research

13 May 2013 • by Natalie Aster

Japan's pharmaceutical industry is the second largest in the world, worth over $89 billion or approximately 10% of the world market. Growth of the domestic pharmaceutical industry has recently been hampered by biennial drug price reductions, which are expected to continue as the government attempts to cut healthcare expenditure. In addition, the gradual increase in market share and competition from generics has depressed market value and will continue to do so as government policy promotes their use.

However, easing of regulatory guidelines, an aging population and a strong product pipeline will provide a strong impetus for growth in the pharmaceutical industry. Although the increasing market share of generics may dampen market value, this represents a great deal of opportunity for generic manufacturers. Historically, the Japanese pharmaceutical market has favored domestic companies. However, increasing deregulation is promoting investment from abroad and hasincreased the presence of foreign firms in the Japanese market.

The report "Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players" by GBI Research assesses the characteristics of the Japanese pharmaceutical market, providing details about recent regulatory changes, the Japanese pharma supply chain and the competitive landscape. It also draws on macroeconomic and demographic factors and the implications on healthcare policy. The report provides detailed analysis of the economic and healthcare challenges facing Japan.

Report Details:

Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players
Published: April, 2013
Pages: 97
Price: US$ 3,500.00

More information can be found in the report “Japan Pharmaceutical Market Outlook - Deregulation and More Efficient New Drug Approval Process Attract Foreign Investment and Improve the Competitiveness of Japanese Players” by GBI Research.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com